AzTrials
AzTrials

HypertensionPhase 4NCT00992056

Nebivolol Versus Metoprolol: Sodium Sensitivity

A Phase 4 study testing nebivolol and Metoprolol in people with Hypertension, run by University of Miami at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Research objectives The objective of this randomized, placebo-controlled, 2 period crossover clinical trial is to determine the effects of nebivolol versus metoprolol on ambulatory blood pressure, the blood pressure response to dietary sodium loading, and renal handling of an acute sodium load in postmenopausal women… Read more about this study

Who is it for?
Ages 46 years and older, women only
Conditions the study is for
Hypertension
What is being tested?
nebivolol and Metoprolol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteUnited States
Study dates
Dec 2010to May 2012
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 46 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Women > 45 years of age.
  • Self-identified as Hispanic ethnicity.
  • Have hypertension defined as:
  • Systolic blood pressure 140-159 mm Hg off antihypertensive medications
  • Diastolic 90-99 mm Hg off antihypertensive medications
  • Blood pressure will be calculated as the mean of 3 consecutive office cuff measurements at rest (sitting). In order to be eligible for treatment, subjects must meet the above definition of hypertension at screening visits off antihypertensive medications
Show all 12Show fewer
  • Natural menopause at least 1 year (no menstruation for 1 year) prior to screening or had a bilateral oophorectomy at least 3 months prior to study participation.
  • No clinically significant or unstable coexisting medical condition in the estimation of the study PI
  • No clinically significant abnormalities of physical exam or laboratory data in the estimation of the PI
  • Concomitant medications will be evaluated on a case by case basis by the study PI
  • Renal function as assessed by a Cockcroft-Gault estimated glomerular filtration rate (GFR) of >70 ml/min
  • Signed informed consent and the ability to understand the study and its procedures

Who cannot join

  • Inability to understand the study or provide informed consent
  • History of adverse effects or intolerance to nebivolol or beta-blockers
  • Previous treatment with nebivolol within the preceding six months.
  • Significant or unstable cardiovascular, pulmonary, renal, gastrointestinal, hepatic, endocrine, or central nervous system as determined by the principal investigator.
  • Clinically significant abnormalities of physical examination or laboratory data as determined by the principal investigator.
  • The subject has donated or lost more than 450 mL of blood or has received transfusion of any blood or blood products within 30 days prior to screening.
Show all 11Show fewer
  • Receiving treatment with diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, steroids, or other agents known to influence blood pressure, renal function, or sodium sensitivity. Any concomitant medications will be reviewed by the study PI on a case-by-case basis. In general, no concomitant medication is preferred. Any medication may be tapered/discontinued with consent of patient and at the discretion of the study PI.
  • Grapefruit and Seville oranges are not allowed at any time during the study.
  • Any disease or condition that, in the opinion of the investigator, could compromise the absorption, accumulation, metabolism, or excretion of the study medication.
  • Current alcohol or drug abuse.
  • Smoking of more than 10 cigarettes per day.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Division of Clinical Pharmacology Clinical Pharmacology Research Unit (CPRU) 1500 NW 12th Ave 15-West.

    Miami, Florida, 33136

Other trials in United States

About this study

Official title: Comparative Effects of Nebivolol Versus Metoprolol on Sodium Sensitivity and Renal Sodium Handling in Hypertensive Hispanic Postmenopausal Women

Research objectives

The objective of this randomized, placebo-controlled, 2 period crossover clinical trial is to determine the effects of nebivolol versus metoprolol on ambulatory blood pressure, the blood pressure response to dietary sodium loading, and renal handling of an acute sodium load in postmenopausal women with hypertension.

Read more

Hypothesis

Nebivolol will result in a blunted response of blood pressure to oral sodium administration and improved renal handling of an intravenous sodium load in comparison with metoprolol in hypertensive postmenopausal women.

Research plan

Study design

The study consisted of a randomized crossover trial of the effects on sodium sensitivity and renal sodium handling of nebivolol versus metoprolol. All study procedures were carried out under the direct supervision of the Principal Investigator in the outpatient and inpatient research unit of the University of Miami Division of Clinical Pharmacology.

Primary endpoint

Change in 24-hour mean systolic blood pressure determined by 24-hour ambulatory blood pressure monitor (ABPM) from the final day of low sodium to the final day of high sodium in nebivolol versus metoprolol

Read the detailed description

This investigation consisted of a randomized, open-label, 2-Treatment Period (metoprolol versus nebivolol) crossover clinical trial conducted in postmenopausal women with stage 1 hypertension. Nineteen of 24 participants completed all phases of the protocol and had 4 technically adequate ABPM determinations.

Each randomized 4-week Treatment Period was with either nebivolol 5 mg daily titrated to 10 mg daily versus metoprolol 50 mg daily increased to 100 mg. Participants were randomly assigned in blocks of 2 to either arm of the crossover trial: Metoprolol/Nebivolol or Nebivolol/Metoprolol.

Participants returned at weekly (7 days ± 4 days) intervals during all outpatient study phases. On the day of a scheduled visit, participants were instructed not to take their medication at home, but to bring the medication with them to the visit. Participant visits were scheduled in the morning and all evaluations were performed at drug trough (24 ± 2 hours after the previous day's dose). Medications for that day were administered after all evaluations planned for that visit had been completed. At each visit participants were questioned directly about compliance and any missed or delayed doses. In addition pill counts were conducted at each visit.

Eleven-day Inpatient Confinement Period Both 4-week outpatient Treatment Periods were followed by an 11-day inpatient confinement period in the clinical pharmacology research unit (CPRU). During Days 1-5 participants received a diet designed to contain approximately 30 mmol Na and 50 mmol K. On Day 5 a determination of 24-hour ABPM was performed while continuing to receive this low sodium diet. During Days 6-10 participants received a diet designed to contain approximately 200 mmol Na and 50 mmol K. On Day 10 of this high sodium period ABPM was performed while the subjects continued to receive the 200 mmol Na and 50 mmol K diet. The response to increased dietary sodium was defined as the difference between the ABPM measurements conducted on Day 5 and Day 10. On day 11 a sodium handling study was performed to determine the effects of nebivolol versus metoprolol on sodium excretion (UnaV) following 1 liter 0.9% saline administered over 2 hours. All meals were designed with the supervision of a certified dietitian, provided by the University of Miami Hospital Food Service, and directly supervised by CPRU staff.

Renal sodium handling following a 1 L saline challenge. On Day 11 of the inpatient confinement period, while continuing to receive the 200 mmol Na 50 mmol K diet, an intravenous saline load test was performed. Beginning at approximately 0600, baseline urine for sodium, potassium, and creatinine was collected for two hours. At the midpoint of this 2-hour urine collection, blood was taken for sodium, potassium, and creatinine. At approximately 0800 1 L 0.9% normal saline was infused over 2 hours. Urine collections were performed hourly for six one-hour periods for sodium, potassium, and creatinine. Hour 1 and 2 collections were during the saline infusion. Hour 3-6 collections were post saline infusion. Blood pressure and heart rate were determined at baseline and at each hour during the collection period.

At hour 1 midpoint (30 minutes after the infusion was started), and the midpoint of each hourly urine collection for a total of 6 collection periods, blood was taken for creatinine, sodium, and potassium. Immediately following the 6 one-hour collection periods, the subject resumed the standard diet. Meals were identical and served at the same time on Day 11 for both periods. Urine was then collected and volume recorded at intervals of 6-8 hours, 8-12 hours and 12-24 hours. Aliquots were sent for creatinine, sodium, and potassium.

Nebivolol was provided in 5, 10 and 20 mg tablets by Forest Laboratories, New York, New York. Metoprolol ER was purchased as the generic product in 25, 50 and 100 mg tablets.

Conditions
Hypertension
Being tested
nebivolol, Metoprolol
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • nebivololDrug

    Also called Bystolic

    5 mg titrated to 10 mg daily versus matching placebo

  • MetoprololDrug

    Also called Toprol

    Metoprolol 50 mg titrated to 100 mg

Study groups in NCT00992056
Study groupRoleWhat they receive
Metoprolol/NebivololExperimentalMetoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
Receives: Drug: nebivolol; Drug: Metoprolol
Nebivolol/MetoprololExperimentalMetoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
Receives: Drug: nebivolol; Drug: Metoprolol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in 24-hour Mean Systolic Blood Pressure by ABPM From Day 5 of Low Sodium to Day 10 of High Sodium

    Measured: Day 5, Day 10

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2009 (estimated)
  2. Study startDec 2010
  3. Primary completionFeb 2012
  4. Study completionMay 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00992056
Sponsor's protocol ID
20090654
Status last verified
May 2017
First submitted
7 Oct 2009
Last updated
8 Jun 2017
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing nebivolol and Metoprolol in people with Hypertension, run by University of Miami at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Jun 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in 24-hour Mean Systolic Blood Pressure by ABPM From Day 5 of Low Sodium to Day 10 of High Sodium (time frame: Day 5, Day 10). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in